Braxia Scientific Reports Fourth Quarter and FY 2022 Financial Results
Achieved Health Canada Special Access Program approval to provide psilocybin-assisted therapy for depression in Ontario Completed more than 6,000 treatments to date; expanded clinic footprint increasing capacity and greater access to network of mental health specialists Reported positive preliminary results from the first Health Canada Approved, Phase II, randomized clinical trial of multi-dose psilocybin-assisted therapy for Treatment-Resistant-Depression TORONTO, ONTARIO July 29, 2022 – Braxia Scientific Corp. (“Braxia Scientific”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research company with clinics providing innovative ketamine and psilocybin treatments for depression and related disorders, today announced the filing of its audited financial statements and management discussion and analysis for the year ended March 31, 2022. Complete financial statements along with related management discussion and analysis can be found in the System for Electronic Document Analysis and Retrieval (SEDAR), the electronic filing...